ArticleOncology letters2012
Meta-analysis of the expression of the mitosis-related gene Fam83D.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.Breast cancer research : BCR · 2024Article
- FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma.Bioscience reports · 2019Article
- Article
- FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance.Oncotarget · 2016Review
- Article
- ABCG2 is a potential marker of tumor-initiating cells in breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma.Oncotarget · 2015Article
- Decreased expression of EFS is correlated with the advanced prostate cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Multi-omics approach to infer cancer therapeutic targets on chromosome 20q across tumor types.Advances in modern oncology researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The family with sequence similarity 83, member D (Fam83D) encodes a mitotic spindle-associated protein. Its knockdown results in shorter spindles that fail to organize a correct metaphase plate. In this study, we demonstrated that Fam83D is coexpressed with well-known mitotic genes. Pathway analysis results also showed that cell cycle- and mitosis-related pathways are enriched with Fam83D-coexpressed genes. Furthermore, Fam83D is differentially expressed in various types of cancers. The results presented in this study suggest that Fam83D may be an important molecule for mitotic progression and equal segregation of chromosomes. Since the molecules that are involved in these mechanisms are crucial for mitosis as well as carcinogenesis, Fam83D should be considered as a novel regulator of mitosis and a putative carcinogenesis-related gene.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.